CoChat

Criteria for Scientific Evaluation of Novel Markers: A Perspective

Moons, Karel GM · 2010 · Clinical Chemistry
Cited by 70

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Reports of novel (bio)markers are abundant in the medical literature. These markers range from simple blood or urine markers to those obtained from, e.g., genomics, proteomics, and imaging techniques; and they vary in accuracy, invasiveness of measurement, and cost. The challenge for clinicians and medical researchers is to optimally exploit existing and new markers or tests. The American Heart Association recently issued a guideline with recommendations for research on prognostic markers for cardiovascular outcomes. I elaborate on various aspects of this guideline, extend it to other types of markers and other clinical domains, and add various recommendations to further guide researchers, practicing physicians and laboratory workers involved in the study, application, or measurement of markers. One can hardly open a medical journal without encountering an article describing a novel (bio)marker or a potential causal or predictive role of an existing marker for a given outcome. A quick Medline search on “biomarker” yielded 466 400 hits, and if the search was restricted to the year 2009, 30 146 hits (through December 31). These markers range from simple blood or urine markers to those obtained from, e.g., genomics, proteomics, and electrophysiology and imaging techniques. They can vary markedly in accuracy, invasiveness of measurement, and cost. Because of liberal guidelines for their introduction, new markers or tests are often presented too early to the medical profession, potentially leading to overuse and, thus, extra burden and costs to patients, the healthcare industry, and the economy. The challenge for clinicians and medical researchers is how to optimally apply existing and new markers/tests; meeting this challenge, however, requires rigorous evaluation of markers and tests. Whereas methods for drug research are well established, a proper framework to quantify the clinical value of (novel) markers or tests is both currently underdeveloped and urgently needed. Recently, Hlatky and colleagues on behalf of the American Heart Association issued a statement containing criteria for phased evaluation of novel markers of cardiovascular risk, with clear recommendations for each phase (1). These criteria are excellent, but as with every guideline, some aspects are not fully addressed and some must be added. Below, I elaborate on some of these criteria and add various recommendations to further guide researchers, practicing physicians, and laboratory workers involved in the study, application, or measurement of biomarkers. Although I do not intend to review all literature on methods for marker or test research, the Appendix includes additional references ordered per topic addressed below.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2009.134155

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 70

Metadata

Authors
Moons, K. G.
Venue
Clinical Chemistry
Published
2010-04-01
Volume
56
Issue
4
Pages
537-541
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2161799115
Cited by
70
References
14
FWCI
9.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Criteria for Scientific Evaluation of Novel Markers: A Perspective. https://app.cochat.ai/papers/10.1373/clinchem.2009.134155
The paper
Moons, K. G. (2010). Criteria for Scientific Evaluation of Novel Markers: A Perspective. Clinical Chemistry. https://doi.org/10.1373/clinchem.2009.134155

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.